In a documented clinical case report, an unprecedented approach involving the combination of the anti-PD-1 antibody nivolumab and the anti-CTLA4 antibody ipilimumab was administered to a surgical patient diagnosed with HNSCC. This evidence concerns the gene CTLA4 and head and neck squamous cell carcinoma.